SG11202112873RA - Bryostatin compounds for enhancement of immunotherapy - Google Patents

Bryostatin compounds for enhancement of immunotherapy

Info

Publication number
SG11202112873RA
SG11202112873RA SG11202112873RA SG11202112873RA SG11202112873RA SG 11202112873R A SG11202112873R A SG 11202112873RA SG 11202112873R A SG11202112873R A SG 11202112873RA SG 11202112873R A SG11202112873R A SG 11202112873RA SG 11202112873R A SG11202112873R A SG 11202112873RA
Authority
SG
Singapore
Prior art keywords
immunotherapy
enhancement
bryostatin compounds
bryostatin
compounds
Prior art date
Application number
SG11202112873RA
Inventor
Paul Wender
Akira J Shimizu
Clayton Hardman
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG11202112873RA publication Critical patent/SG11202112873RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202112873RA 2019-05-21 2020-05-19 Bryostatin compounds for enhancement of immunotherapy SG11202112873RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962850905P 2019-05-21 2019-05-21
PCT/US2020/033638 WO2020236833A1 (en) 2019-05-21 2020-05-19 Bryostatin compounds for enhancement of immunotherapy

Publications (1)

Publication Number Publication Date
SG11202112873RA true SG11202112873RA (en) 2021-12-30

Family

ID=73459448

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112873RA SG11202112873RA (en) 2019-05-21 2020-05-19 Bryostatin compounds for enhancement of immunotherapy

Country Status (10)

Country Link
US (1) US20220193029A1 (en)
EP (1) EP3972585A4 (en)
JP (1) JP2022533412A (en)
CN (1) CN114072141A (en)
AU (1) AU2020277375A1 (en)
CA (1) CA3140621A1 (en)
IL (1) IL287179A (en)
MX (1) MX2021014103A (en)
SG (1) SG11202112873RA (en)
WO (1) WO2020236833A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038532A1 (en) * 2016-10-05 2018-04-12 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
AU2020363734A1 (en) * 2019-10-10 2022-05-19 Bryologyx Inc. Method of induction of tumor associated antigens with bryostatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673838B2 (en) * 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ Immunotherapy cells engineered to target antigens present on both immune and diseased cells
CA3038532A1 (en) * 2016-10-05 2018-04-12 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
JP7314115B2 (en) * 2017-03-31 2023-07-25 セレクティス ソシエテ アノニム Universal anti-CD22 chimeric antigen receptor engineered immune cells
US11939377B2 (en) * 2018-07-12 2024-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof

Also Published As

Publication number Publication date
JP2022533412A (en) 2022-07-22
CN114072141A (en) 2022-02-18
IL287179A (en) 2021-12-01
EP3972585A4 (en) 2023-06-21
MX2021014103A (en) 2021-12-15
EP3972585A1 (en) 2022-03-30
AU2020277375A1 (en) 2022-01-27
WO2020236833A1 (en) 2020-11-26
US20220193029A1 (en) 2022-06-23
CA3140621A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
IL292754A (en) Method of synthesis
SG11202002395UA (en) Blockchain-based service of process
EP3766529A4 (en) Composition for purification of biofluids
EP3712130A4 (en) Method for synthesis of roxadustat and intermediate compounds thereof
EP3611171A4 (en) Method for synthesis of eliglustat and intermediate compounds thereof
IL287179A (en) Bryostatin compounds for enhancement of immunotherapy
EP3717457A4 (en) Process for preparation of enzalutamide using novel intermediate
GB201904612D0 (en) Reaction of glycoladehyde
IL290367A (en) Fused ring heteroaryl compounds as ripk1 inhibitors
EP3747433A4 (en) Combination of cellular immunotherapy
EP3823973A4 (en) Purification process for preparation of eribulin and intermediates thereof
EP3897660A4 (en) Novel crystalline forms of an nrtti compound
IL290181A (en) Process for the preparation of fluensulfone
IL285219A (en) Crystal of diarylthiohydantoin compound
EP3820881A4 (en) Novel polymorphic forms of cyclo (-his-pro)
EP3864011A4 (en) Process for preparation of eribulin and intermediates thereof
GB201906840D0 (en) Method of deposition
EP3762356A4 (en) Improved process for preparation of intermediates
EP3989975A4 (en) Process for preparation of abrocitinib
EP4003962A4 (en) Process for synthesis of pyrazolidinone compounds
SG11202108320PA (en) Method of selecting for antibodies
GB201903055D0 (en) Method of oligonucleaotide synthesis
GB201912411D0 (en) Crystalline forms of ivosidenib
EP3752181A4 (en) Immunotherapy of leishmaniasis
GB201910664D0 (en) Novel forms of compound